Genome-wide association studies (GWAS) have started revealing hundreds of associations between genetic variants and phenotypes ( 1 , 2 ). Most associations have robust statistical support in the populations where they have been examined. However, almost all GWAS published to date were performed in populations of European ancestry, and the replication efforts in the original publications also focused primarily on similar populations. Are these discovered associations relevant for populations of different ancestry?
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In this issue, a study by Yamada et al. ( 3 ) evaluated in Japanese participants 23 single-nucleotide polymorphisms (SNPs) that had been identifi ed in the GWAS era. Of those, 16 had emerged originally from studies of European descent populations, two from African descent populations, and fi ve from studies addressing diverse populations. Seven of these 23 SNPs (fi ve independent loci) showed nominally statistically signifi cant associations ( P < .05) with prostate cancer risk in the Japanese population. The other 16 SNPs were not associated with prostate cancer risk, and in fi ve of those, the point estimates of the odds ratios (ORs) were in opposite direction than previously described.
Do these results herald extensive nonreplication vs the original discoveries? Not necessarily. One can estimate the power of Yamada et al. (311 case patients and 1035 control subjects) to detect ORs similar to those previously found, given the allele frequencies observed in the Japanese population. I used the per-allele ORs found in European descent populations ( 1 , 4 , 5 ) in 21 previously evaluated SNPs for a comparison against the Japanese data ( Figure 1 ). Estimated power ( 6 ) at alpha value of .05 ranges from almost 0% for rs4962416, which has a 1% risk allele frequency in the Japanese population, to practically 100% for rs16901979, for which the previously proposed OR was large (1.79) and the risk allele frequency in the Japanese population is 19%. If we sum the power estimates for all SNPs to detect the respective ORs previously seen in European descent participants, we can estimate that if ORs were identical in the Japanese population, ( 5 ) (rs7920517) when entries were not found in the NHGRI catalog. The odds ratio and control group frequency of the same allele (the one that confers risk in populations of European descent) in the Japanese population is from the study by Yamada et al. ( 3 ) . The data are shown by fi lled circles. The boxed number neighboring each data point shows the estimated power (in percent) at alpha value of .05 to detect the odds ratio of the Europeans also in the Japanese, given the risk allele frequency observed in the Japanese control subjects in the study by Yamada et al. Power calculations with the PS software ( 6 ) are for Fisher exact test based on allele counts; results for 2 were either identical or slightly larger (data not shown). For rs4962416, the statistical power was too small to be estimated for standard Fisher application, given that the minor allele frequency is only 1% (power shown here as 0%). Populations of European descent have been sampled either from Europe per se or from North America or Australia.
For Overall correlation between ORs in the two ancestry groups is modest (Pearson correlation coeffi cient = .45, P = .04; Figure 1, A ) . For the same variants, correlation is even weaker for the allele frequencies (correlation coeffi cient = .30, P = .18; Figure 1, B ) . Some risk alleles may confer the same OR in both populations, but their population-specifi c frequencies may vary substantially. This situation (varying frequency, similar OR) has been previously well documented for candidate gene variants ( 7 ), and the same phenomenon appears now for GWAS-discovered markers, for example, rs16901979 consistently confers an OR of approximately 1.8 in both populations, but the risk allele is more common in the Japanese population than in populations of European descent (19% vs 3%). Conversely, rs721048 confers modest risk in both populations, but it is more common in populations of European descent than in the Japanese population (19% vs 4%).
Data are more limited in populations of African descent, which is unfortunate, because the haplotypic structure of African populations would be ideally suited for making specifi c discoveries ( 8 ) . Differences may be even greater in populations of African descent vs other populations ( 4 ). One of the tested SNPs (Broad11934905) originally found in African populations was monomorphic in the Japanese population.
These data reinforce the notion that discovered variants in the GWAS setting are often simply population-specifi c markers that need far more effort to lead to functional culprits ( 9 ) . However, even functional culprits may differ across populations, and some may exist only in specifi c populations. Population diversity could have implications about the utility of GWAS-derived information for predictive purposes. Despite high expectations, discovered variants contribute small quanta to the disease risk of each individual. Using single or very few variants for predictive purposes is ineffi cient and useless or even misleading for any population ( 10 -12 ) . The question is whether predictive ability may reach suffi cient performance once many such variants are considered ( 13 ) . Would results be generalizable across populations?
Yamada et al. used information from the fi ve nonoverlapping SNPs in the Japanese population to construct a predictive model in which men with six or more risk alleles (top 11%) had 6.22-fold greater odds of having prostate cancer compared with those with two or fewer alleles (lower 20% of control subjects). This discriminatory ability seems superior to what has been described in populations of European descent ( 14 ) , among whom having seven SNPs resulted in an OR of approximately 3.5 for the top 1% vs the lower 1% of genetic risk and among whom was estimated that 15 SNPs would barely achieve an OR of 2.1 for the top 10% vs the population average. The higher OR found by Yamada et al. may mean that better discrimination is feasible to achieve in the Japanese population or the effect sizes of the fi ve nominally statistically signifi cant SNPs are infl ated compared with their true values. When markers are selected based on their ability to pass a desired threshold of statistical signifi cance, their observed effect sizes are on average larger than the true estimates ( 15 , 16 ) . Understanding the exact ability of these markers to discriminate between prostate cancer case patients and control subjects has to wait for yet another independent validation sample.
Ideally, understanding precise effect sizes for these variants and their combined effects will require large studies and extensive replication in diverse populations ( 17 ) and careful synthesis of all the accumulated evidence ( 18 ) . Although we have found many promising markers for prostate cancer and other diseases through GWAS, and these have been replicated in similar populations, this is just the beginning. The fi ndings need to be replicated again and then again validated.
